Literature DB >> 33407171

Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis.

Mei Luo1, Xiaojun Zhuang1, Zhenyi Tian1, Lishou Xiong2.   

Abstract

BACKGROUND: Short-chain fatty acids (SCFAs) and serotonin (5-hydroxytryptamine, 5-HT) may be associated with the pathogenesis of irritable bowel syndrome (IBS). There are some reports of alterations in SCFAs and 5-HT in IBS, but their results are inconsistent. We aimed to perform a meta-analysis to assess alterations in SCFAs and 5-HT in IBS patients and their potential role in the abnormal brain-gut-microbiota (BGM) axis.
METHODS: Case-control studies detecting SCFAs and 5-HT in IBS patients were identified from PubMed, Web of Science, Cochrane Library, and Scopus databases to identify relevant articles up to September 2018. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) of SCFAs and 5-HT were calculated by REVIEW MANAGER 5.3 to evaluate the alterations of 5-HT and SCFAs in IBS.
RESULTS: Five studies on SCFAs and 5 on 5-HT in IBS patients were included. As compared to healthy controls (HCs), the SMDs of 5-HT in IBS patients was 2.35 (95% CI 0.46-4.24) and the SMDs of total SCFAs, acetic acid, propionic acid, and butyric acid in IBS patients were - 0.01 (95% CI - 0.57-0.55), - 0.04 (95% CI - 0.55-0.47), 0.07 (95% CI - 0.45-0.60), and - 0.00 (95% CI - 0.49-0.49), respectively.
CONCLUSIONS: There was an increase in 5-HT in blood of IBS patients, indicating the increased 5-HT in blood may be involved in IBS pathogenesis. However, there were no significant differences in SCFAs in feces between IBS patients and HCs. But the study did not differentiate between subgroups of IBS. These findings might provide insight for future studies of the BGM axis in the pathogenesis of IBS. Mei Luo and Xiaojun Zhuang contributed equally to the writing of this article.

Entities:  

Keywords:  Brain-gut-microbiota axis; Irritable bowel syndrome; Meta-analysis; Serotonin; Short-chain fatty acids

Mesh:

Substances:

Year:  2021        PMID: 33407171      PMCID: PMC7788881          DOI: 10.1186/s12876-020-01577-5

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  63 in total

Review 1.  Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour.

Authors:  John F Cryan; Timothy G Dinan
Journal:  Nat Rev Neurosci       Date:  2012-09-12       Impact factor: 34.870

2.  Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome.

Authors:  T Banasiewicz; Ł Krokowicz; Z Stojcev; B F Kaczmarek; E Kaczmarek; J Maik; R Marciniak; P Krokowicz; J Walkowiak; M Drews
Journal:  Colorectal Dis       Date:  2013-02       Impact factor: 3.788

3.  Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls.

Authors:  Sunil Kumar; Prabhat Ranjan; Balraj Mittal; Uday C Ghoshal
Journal:  J Gastrointestin Liver Dis       Date:  2012-03       Impact factor: 2.008

Review 4.  The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism.

Authors:  Gijs den Besten; Karen van Eunen; Albert K Groen; Koen Venema; Dirk-Jan Reijngoud; Barbara M Bakker
Journal:  J Lipid Res       Date:  2013-07-02       Impact factor: 5.922

Review 5.  Functional bowel disorders.

Authors:  George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study.

Authors:  C P Bearcroft; D Perrett; M J Farthing
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

7.  Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome.

Authors:  C Tana; Y Umesaki; A Imaoka; T Handa; M Kanazawa; S Fukudo
Journal:  Neurogastroenterol Motil       Date:  2009-11-10       Impact factor: 3.598

8.  Faecal weight, constituents, colonic motility, and lactose tolerance in the irritable bowel syndrome.

Authors:  M A Eastwood; B A Walton; W G Brydon; J R Anderson
Journal:  Digestion       Date:  1984       Impact factor: 3.216

9.  Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome.

Authors:  L A Houghton; W Atkinson; R P Whitaker; P J Whorwell; M J Rimmer
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Decreased levels of kynurenic acid in the intestinal mucosa of IBS patients: relation to serotonin and psychological state.

Authors:  Daniel Keszthelyi; Freddy J Troost; Daisy M Jonkers; Joanna W Kruimel; Carsten Leue; Ad A M Masclee
Journal:  J Psychosom Res       Date:  2013-02-15       Impact factor: 3.006

View more
  2 in total

Review 1.  Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota-Gut-Brain Axis.

Authors:  Elena Layunta; Berta Buey; Jose Emilio Mesonero; Eva Latorre
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-08       Impact factor: 5.555

2.  Microbiome, Mycobiome and Related Metabolites Alterations in Patients with Metabolic Syndrome-A Pilot Study.

Authors:  Gratiela Gradisteanu Pircalabioru; Iuliana Ilie; Luciana Oprea; Ariana Picu; Laura Madalina Petcu; Liliana Burlibasa; Mariana-Carmen Chifiriuc; Madalina Musat
Journal:  Metabolites       Date:  2022-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.